MedPath

Roluperidone

Generic Name
Roluperidone
Drug Type
Small Molecule
Chemical Formula
C22H23FN2O2
CAS Number
359625-79-9
Unique Ingredient Identifier
4P31I0M3BF
Background

Roluperidone has been used in trials studying the treatment of Schizophrenia.

Clinical Trials
Related News

A Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Co-Administration of Roluperidone and Olanzapine in Adult Subjects With Moderate to Severe Negative Symptoms of Schizophrenia

Phase 1
Completed
Conditions
Negative Symptoms in Schizophrenia
Interventions
First Posted Date
2023-10-30
Last Posted Date
2025-03-26
Lead Sponsor
Minerva Neurosciences
Target Recruit Count
17
Registration Number
NCT06107803
Locations
🇺🇸

Collaborative Neuroscience Research, LLC, Garden Grove, California, United States

🇺🇸

CBH Health, LLC, Gaithersburg, Maryland, United States

🇺🇸

Hassman Research Institute, Marlton, New Jersey, United States

Study to Evaluate Efficacy and Safety of Roluperidone (MIN-101) in Adult Patients With Negative Symptoms of Schizophrenia

Phase 3
Completed
Conditions
Negative Symptoms of Schizophrenia
Interventions
Drug: Placebo Oral Tablet
First Posted Date
2018-01-11
Last Posted Date
2023-04-28
Lead Sponsor
Minerva Neurosciences
Target Recruit Count
515
Registration Number
NCT03397134
Locations
🇺🇸

Collaborative Neuroscience Network, LLC., Torrance, California, United States

🇺🇸

Atlanta Center for Medical Research, Atlanta, Georgia, United States

🇺🇸

Uptown Research Institute LLC, Chicago, Illinois, United States

and more 34 locations

A Pharmacokinetic Study of MIN-101 and Its Metabolites in Healthy Subjects to Compare MIN-101 in Poor and Extensive Metabolizers

Phase 1
Completed
Conditions
Healthy Subjects
Interventions
First Posted Date
2017-03-07
Last Posted Date
2017-08-31
Lead Sponsor
Minerva Neurosciences
Target Recruit Count
23
Registration Number
NCT03072056
Locations
🇮🇪

Biokinetic Europe, Belfast, Ireland

A Pharmacokinetic Study of Modified Release (MR) Formulations of MIN-101 in Healthy Subjects

Phase 1
Completed
Conditions
Healthy Subjects
Interventions
First Posted Date
2017-02-01
Last Posted Date
2017-08-31
Lead Sponsor
Minerva Neurosciences
Target Recruit Count
14
Registration Number
NCT03038646
Locations
🇮🇪

Biokinetic Europe, Belfast, Ireland

Pharmacokinetic Study of MIN-101 in Healthy Subjects

Phase 1
Completed
Conditions
Schizophrenia
Interventions
Drug: Placebo
First Posted Date
2014-09-05
Last Posted Date
2015-02-24
Lead Sponsor
Minerva Neurosciences
Target Recruit Count
32
Registration Number
NCT02232529
Locations
🇬🇧

Quotient Clinical, Ruddington, Nottingham, United Kingdom

Study of CYR-101 in Patients With Schizophrenia

Phase 2
Completed
Conditions
Schizophrenia
Interventions
Drug: Placebo
First Posted Date
2009-03-13
Last Posted Date
2011-06-08
Lead Sponsor
Cyrenaic Pharmaceuticals
Target Recruit Count
100
Registration Number
NCT00861796
Locations
🇫🇷

Centre Hospitalier Universitaire de Nancy (CHU), Toul, France

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy